Myrcludex B is a drug against hepatitis
B and hepatitis D.
The medication developed by DZIF scientists prevents hepatitis
B viruses and hepatitis D viruses from entering liver cells. Co-infection
of hepatitis B and hepatitis D presents the most serious form of viral hepatitis and was untreatable until then. Myrcludex B is a substance well tolerated by humans and it prevents viral reproduction.